Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 15.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 219,793 shares of the company’s stock after acquiring an additional 29,000 shares during the quarter. New York State Common Retirement Fund’s holdings in Roivant Sciences were worth $2,600,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the period. Covestor Ltd lifted its holdings in shares of Roivant Sciences by 9.1% in the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after buying an additional 1,605 shares during the period. US Bancorp DE lifted its holdings in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares during the period. Quarry LP lifted its holdings in shares of Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences in the 3rd quarter valued at approximately $35,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $10.74 on Friday. The stock has a fifty day moving average price of $11.08 and a 200 day moving average price of $11.58. The stock has a market cap of $7.66 billion, a PE ratio of -71.60 and a beta of 1.25. Roivant Sciences Ltd. has a 1 year low of $9.76 and a 1 year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

ROIV has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $18.08.

Insider Buying and Selling

In related news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CIO Mayukh Sukhatme sold 412,584 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total value of $4,971,637.20. Following the transaction, the executive now directly owns 18,836,547 shares of the company’s stock, valued at $226,980,391.35. The trade was a 2.14 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,388,170 shares of company stock valued at $27,612,299. 7.90% of the stock is owned by insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.